451 related articles for article (PubMed ID: 21933973)
1. Targeting Axl and Mer kinases in cancer.
Verma A; Warner SL; Vankayalapati H; Bearss DJ; Sharma S
Mol Cancer Ther; 2011 Oct; 10(10):1763-73. PubMed ID: 21933973
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Mer and Axl receptor tyrosine kinases leads to increased apoptosis and improved chemosensitivity in human neuroblastoma.
Li Y; Wang X; Bi S; Zhao K; Yu C
Biochem Biophys Res Commun; 2015 Feb; 457(3):461-6. PubMed ID: 25596315
[TBL] [Abstract][Full Text] [Related]
3. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.
Linger RM; Keating AK; Earp HS; Graham DK
Expert Opin Ther Targets; 2010 Oct; 14(10):1073-90. PubMed ID: 20809868
[TBL] [Abstract][Full Text] [Related]
4. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.
Linger RM; Keating AK; Earp HS; Graham DK
Adv Cancer Res; 2008; 100():35-83. PubMed ID: 18620092
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of hepatic physiology and injury by the TAM receptors Axl and Mer.
Zagórska A; Través PG; Jiménez-García L; Strickland JD; Oh J; Tapia FJ; Mayoral R; Burrola P; Copple BL; Lemke G
Life Sci Alliance; 2020 Aug; 3(8):. PubMed ID: 32571802
[TBL] [Abstract][Full Text] [Related]
6. Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.
Schoumacher M; Burbridge M
Curr Oncol Rep; 2017 Mar; 19(3):19. PubMed ID: 28251492
[TBL] [Abstract][Full Text] [Related]
7. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
Linger RM; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DH; Lu X; Barón AE; Franklin WA; Merrick DT; Jedlicka P; DeRyckere D; Heasley LE; Graham DK
Oncogene; 2013 Jul; 32(29):3420-31. PubMed ID: 22890323
[TBL] [Abstract][Full Text] [Related]
8. Axl kinase as a key target for oncology: focus on small molecule inhibitors.
Feneyrolles C; Spenlinhauer A; Guiet L; Fauvel B; Daydé-Cazals B; Warnault P; Chevé G; Yasri A
Mol Cancer Ther; 2014 Sep; 13(9):2141-8. PubMed ID: 25139999
[TBL] [Abstract][Full Text] [Related]
9. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.
Keating AK; Kim GK; Jones AE; Donson AM; Ware K; Mulcahy JM; Salzberg DB; Foreman NK; Liang X; Thorburn A; Graham DK
Mol Cancer Ther; 2010 May; 9(5):1298-307. PubMed ID: 20423999
[TBL] [Abstract][Full Text] [Related]
11. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
[TBL] [Abstract][Full Text] [Related]
12. Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?
Dransfield I; Farnworth S
Adv Exp Med Biol; 2016; 930():113-32. PubMed ID: 27558819
[TBL] [Abstract][Full Text] [Related]
13. Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells.
Lee YJ; Lim T; Han MS; Lee SH; Baek SH; Nan HY; Lee C
Oncol Rep; 2017 Feb; 37(2):1219-1226. PubMed ID: 28035396
[TBL] [Abstract][Full Text] [Related]
14. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation.
Tsou WI; Nguyen KQ; Calarese DA; Garforth SJ; Antes AL; Smirnov SV; Almo SC; Birge RB; Kotenko SV
J Biol Chem; 2014 Sep; 289(37):25750-63. PubMed ID: 25074926
[TBL] [Abstract][Full Text] [Related]
15. Research Progress of Axl Inhibitors.
Sun ZG; Liu JH; Zhang JM; Qian Y
Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
[TBL] [Abstract][Full Text] [Related]
16. The TAM-family receptor Mer mediates production of HGF through the RhoA-dependent pathway in response to apoptotic cells.
Park HJ; Baen JY; Lee YJ; Choi YH; Kang JL
Mol Biol Cell; 2012 Aug; 23(16):3254-65. PubMed ID: 22740630
[TBL] [Abstract][Full Text] [Related]
17. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.
Waizenegger JS; Ben-Batalla I; Weinhold N; Meissner T; Wroblewski M; Janning M; Riecken K; Binder M; Atanackovic D; Taipaleenmaeki H; Schewe D; Sawall S; Gensch V; Cubas-Cordova M; Seckinger A; Fiedler W; Hesse E; Kröger N; Fehse B; Hose D; Klein B; Raab MS; Pantel K; Bokemeyer C; Loges S
Leukemia; 2015 Mar; 29(3):696-704. PubMed ID: 25102945
[TBL] [Abstract][Full Text] [Related]
18. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
[TBL] [Abstract][Full Text] [Related]
19. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.
Lew ED; Oh J; Burrola PG; Lax I; Zagórska A; Través PG; Schlessinger J; Lemke G
Elife; 2014 Sep; 3():. PubMed ID: 25265470
[TBL] [Abstract][Full Text] [Related]
20. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]